Climb Bio, Inc. CLYM Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Climb Bio, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Climb Bio, Inc.'s stock-based comp?
- Climb Bio, Inc. (CLYM) reported stock-based comp of $1.61M in Q1 2026.
- How has Climb Bio, Inc.'s stock-based comp changed year-over-year?
- Climb Bio, Inc.'s stock-based comp decreased by 20.6% year-over-year, from $2.02M to $1.61M.
- What is the long-term trend for Climb Bio, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Climb Bio, Inc.'s stock-based comp has grown at a 21.2% compound annual growth rate (CAGR), from $3.74M to $8.05M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.